Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPTp-SP with rapid diagnostic test screening and treatment at first antenatal care visit
PACTR201905721140808Phase 3Unknown
- Sponsor
- Tropical Diseases Research Centre
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sulfadoxine + pyrimethamine and dihydroartemisinin + piperaquine in Placental Malaria (PM) and Falciparum malaria (PF), sponsored by Tropical Diseases Research Centre. Primary endpoints: Relative hazard of Plasmodium falciparum infection by PCR at day 42 and Medication-related adverse events and serious adverse events. Status: unknown.
02
Drugs
sulfadoxine + pyrimethaminedihydroartemisinin + piperaquine
03
Conditions
Placental Malaria (PM)Falciparum malaria (PF)
Beyond the preview
Go deeper on PACTR201905721140808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201905721140808.